Report

The United States glucagon-like peptide-1 (GLP-1) agonists market was valued at USD 10.25 Billion in 2024, driven by the rising prevalence of type 2 diabetes and obesity along with the robust regulatory support in the region. The market is anticipated to grow at a CAGR of 8.20% during the forecast period of 2025-2034, with the values likely to reach USD 22.54 Billion by 2034.

United States Glucagon-like Peptide-1 (GLP-1) Agonists Market Overview

The United States is considered the largest and fastest-growing market for glucagon-like peptide-1 (GLP-1) receptor agonists, owing to the rising prevalence of obesity and type 2 diabetes. The increasing demand for advanced weight loss and diabetes treatments is making GLP-1 drugs like Ozempic, Wegovy, and Mounjaro popular among both patients and healthcare providers. The growing regulatory approval for new GLP-1-based drugs is a significant market trend. Additionally, the expanding clinical trials and increasing insurance coverage are poised to boost market growth over the forecast period.

United States Glucagon-like Peptide-1 (GLP-1) Agonists Market Growth Drivers

Rising Prevalence of Diabetes to Support Market Growth

According to the Centers for Disease Control and Prevention (CDC), about 1 in 10 people in the United States are affected by diabetes, accounting for more than 38 million Americans. It is also reported that 90% to 95% of them suffer from type 2 diabetes. The rising diabetes cases are increasing demand for GLP-1 receptor agonists like Ozempic and Mounjaro. Moreover, ongoing drug innovation and rising investments are expected to further expedite the market growth.

United States Glucagon-like Peptide-1 (GLP-1) Agonists Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Substantial Investment to Support R&D and Boost Production

In October 2024, Eli Lilly and Company, the producer of Mounjaro and Zepbound (two leading GLP-1 drugs for diabetes and weight loss), announced a USD 4.5 billion investment in a new research and development center in Lebanon, Indiana. The facility will focus on developing new medicines and scaling up drug production for clinical trials. This investment is expected to strengthen the supply of GLP-1 drugs, along with addressing the rising United States glucagon-like peptide-1 (GLP-1) agonists market demand.

Expanding GLP-1 Drug Indications

In January 2025, the U.S. FDA approved Ozempic for type 2 diabetes patients with kidney disease. This regulatory win marked a major expansion of GLP-1 drug indications beyond diabetes and obesity, introducing a new treatment option to help reduce complications such as heart disease, dialysis, and kidney transplant.

Rising Regulatory Support for Generic GLP-1 Receptor Therapies

The US Food and Drug Administration is prioritizing generic GLP-1 approvals to combat rising demand and supply shortages. Recent approvals of generic liraglutide (Victoza) and exenatide (Byetta) indicate efforts to improve drug accessibility and affordability. This trend is likely to influence the United States glucagon-like peptide-1 (GLP-1) agonists market growth, increasing competition and lowering costs for consumers.

Growing Preference for Long-Acting and Oral GLP-1 Formulations

A key trend in the glucagon-like peptide-1 (GLP-1) agonists market is the rising demand for oral and long-acting formulations as patients and healthcare providers look for more convenient and effective treatment options. While injectable GLP-1 drugs remain common, the market is shifting to oral and extended-release versions, which is poised to impact market dynamics.

United States Glucagon-like Peptide-1 (GLP-1) Agonists Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Drugs

- Dulaglutide
- Exenatide
- Liraglutide
- Tirzepatide
- Lixisenatide
- Semaglutide

Market Breakup by Application

- Type 2 Diabetes Mellitus
- Obesity

Market Breakup by Route of Administration

- Parenteral
- Oral

Market Breakup by End User

- Hospitals
- Specialty Clinics
- Academic and Research Institutes
- Others

Market Breakup by Distribution Channel

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

United States Glucagon-like Peptide-1 (GLP-1) Agonists Market Share

Segmentation Based on Drugs to Witness Substantial Growth

Based on the drugs, the United States market is segmented into dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. Semaglutide holds a significant market share due to its established efficacy and availability of multiple formulations (Ozempic, Wegovy, Rybelsus). On the other hand, dulaglutide is a once-weekly injectable GLP-1 agonist used for type 2 diabetes management. It remains a popular alternative due to its convenience and cardiovascular benefits.

United States Glucagon-like Peptide-1 (GLP-1) Agonists Market Analysis by Region

In the United States, the Northeast and West Coast regions have high adoption rates as a result of better healthcare access and widespread insurance coverage for GLP-1 drugs like Ozempic, Wegovy, and Mounjaro. The Midwest and Southern states are witnessing substantial obesity and type 2 diabetes rates, which is fuelling the market demand in the region. Further, the expansion of pharmaceutical manufacturing facilities in states like North Carolina and Indiana is anticipated to address GLP-1 drug shortages and elevate the market value.

Leading Players in the United States Glucagon-like Peptide-1 (GLP-1) Agonists Market

The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Eli Lilly and Company

Eli Lilly is rapidly expanding its share in the United States market for GLP-1, with Mounjaro (tirzepatide) witnessing high demand for both diabetes and weight management. The company is investing substantially in new manufacturing plants in the region to scale up production and address ongoing GLP-1 drug shortages.

Sanofi

Sanofi is strategically strengthening its presence in the United States glucagon-like peptide-1 (GLP-1) agonists market, focusing on partnerships and pipeline expansion to compete with other key players like Novo Nordisk and Eli Lilly. The company is investing in R&D to develop novel GLP-1 formulations, particularly in once-weekly and oral therapies.

Novo Nordisk A/S

Novo Nordisk is one of the dominating players in the market, with Wegovy and Ozempic experiencing growing demand. To address drug shortages, the company is expanding production facilities and exploring additional supply chain improvements. Novo Nordisk is also partnering with U.S. healthcare providers to increase awareness and accessibility of GLP-1 therapies for obesity treatment.

AstraZeneca plc

AstraZeneca is shifting focus toward GLP-1 combination therapies in the United States, aiming to integrate GLP-1 drugs with cardiovascular and kidney disease treatments. The company is conducting new clinical trials on dual-action metabolic drugs that could complement GLP-1 receptor agonists.

Other key players in the market include Pfizer Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, Amgen Inc., and GlaxoSmithKline plc.

Key Questions Answered in the United States Glucagon-like Peptide-1 (GLP-1) Agonists Market Report

- What was the United States glucagon-like peptide-1 (GLP-1) agonists market value in 2024?
- What is the United States glucagon-like peptide-1 (GLP-1) agonists market forecast outlook for 2025-2034?
- What is the market segmentation based on drugs?
- What is the market segmentation based on application?
- What is the market breakup based on the route of administration?
- What is the market breakup by end user?
- What is the market breakup based on the distribution channel?
- What major factors aid the United States glucagon-like peptide-1 (GLP-1) agonists market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Who are the key players involved in the United States glucagon-like peptide-1 (GLP-1) agonists market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?